Syncona Limited

Syncona Limited is a FTSE250 healthcare company focused on founding, building and funding a portfolio of global leaders in life science. The firm operates as an evergreen investment company and is based in London, UK. The firm seeks to deliver returns from the creation of a sustainable, diverse portfolio of 15-20 companies focused on delivering treatments to patients in innovative areas of healthcare, and makes all-stage venture capital investments and is primarily focused on the UK and Europe. Syncona has a portfolio of 9 life science companies, 6 of which today are in the areas of cell therapy and gene therapy. Syncona takes a long-term view, underpinned by a strategic capital base which provides it with control and flexibility over the management of its life science portfolio. Syncona's purpose is to invest to extend and enhance human life. The firm does this by creating, building and scaling companies to deliver transformational treatments to patients in areas of high unmet need. The firm aims to build and maintain a diversified portfolio of 20-25 globally leading life science businesses, across development stage, modality and therapeutic area, for the benefit of all their stakeholders. They focus on developing treatments that deliver patient impact by working in close partnership with academic founders and experienced management teams. Their balance sheet underpins their strategy, enabling them to take a long-term view as they look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.